7 completed, 4 terminated. 11 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 7, Terminated 4 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Noncutaneous Extranodal Lymphoma: new trials by email Literature Review of Noncutaneous Extranodal Lymphoma trials Research Report on Noncutaneous Extranodal Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 1 | Completed | Wake Forest University Health Sciences | 16 | 2014-09-01 | 2024-02-13 |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Morphotek | 27 | 2013-11-01 | 2016-01-08 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2011-01-01 | 2014-04-29 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy sunitinib malate, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2009-08-01 | 2014-03-17 |
| Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia dexrazoxane hydrochloride, doxorubicin hydrochloride, obatoclax mesylate - Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2009-06-01 | 2014-05-01 |
| Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma bevacizumab, cediranib maleate - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 57 | 2007-05-01 | 2014-02-19 |
| Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma oxaliplatin, etoposide - Angioimmunoblastic T-cell Lymphoma, B-cell Childhood Acute Lymphoblastic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 40 | 2004-11-01 | 2014-02-24 |
| Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 37 | 2003-09-01 | 2020-01-18 |
| Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer total-body irradiation, fludarabine phosphate, cyclosporine - Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 21 | 2000-05-01 | 2020-01-21 |
| Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies indium In 111 anti-CD45 monoclonal antibody BC8, yttrium Y 90 anti-CD45 monoclonal antibody BC8, peripheral blood stem cell transplantation - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 2 | 1999-09-01 | 2021-04-02 |
Lymphoma, Extranodal NK-T-Cell (11) · Lymphoma, Large-Cell, Anaplastic (11) · Mycosis Fungoides (11) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Sezary Syndrome (11) · Burkitt Lymphoma (10) · Immunoblastic Lymphadenopathy (10) · Leukemia, Hairy Cell (10) · Leukemia, Large Granular Lymphocytic (10) · Lymphoma, Large B-Cell, Diffuse (10) · Lymphoma, T-Cell, Peripheral (10) · Intraocular Lymphoma (9) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Lymphoma, T-Cell, Cutaneous (9) · Hodgkin Disease (8)
Hematologic Diseases (11) · Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Leukemia (11) · Leukemia, Lymphoid (11) · Lymphatic Diseases (11) · Lymphoma (11) · Lymphoma, T-Cell (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · DNA Virus Infections (10) · Disease Attributes (10) · Herpesviridae Infections (10)
Peripheral Blood Stem Cell Transplantation (3) · Cyclosporine (2) · Mycophenolic Acid (2) · Whole-Body Irradiation (2) · fludarabine phosphate (2) · Bendamustine Hydrochloride (1) · Bevacizumab (1) · Brentuximab Vedotin (1) · Dexrazoxane (1) · Doxorubicin (1) · Etoposide (1) · Indium (1) · MK 2206 (1) · Oxaliplatin (1) · Razoxane (1)
National Cancer Institute (NCI) (5) · Fred Hutchinson Cancer Center (3) · Morphotek (1) · Northwestern University (1) · Wake Forest University Health Sciences (1)
United States (11) · Canada (2) · Italy (2) · Germany (1)
Adam Petrich, MD (1) · Ajay Gopal (1) · Brenda Sandmaier (1) · David Hong (1) · David Maloney (1) · John Deeken (1) · Lisa McGregor (1) · Maryam Fouladi (1) · Rakhee Vaidya (1) · Richard Aplenc (1) · Robin Norris (1)
PMID 32499241, PMID 22259028, PMID 23393050, PMID 24474568, PMID 29292843
P30CA015704 (3), U01CA097452 (3), P01CA018029 (1), P01CA044991 (1), P01CA078902 (1), P30CA012197 (1), P30CA016672 (1), P30CA021765 (1), U01CA062461 (1), U01CA121947 (1)